Genetics testing company Pathway Genomics, which saw its retail marketing plans blocked five years ago, has again drawn FDA attention. The agency moved this week to notify the company that its new cancer screening kit lacks needed FDA approval for what the agency views as a high-risk test.
An untitled letter dated Sept. 21 targets Pathway’s CancerIntercept Detect, a blood test that the firm says can...